X

Trial Profile

Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary)
Indications HIV infections
Focus Therapeutic Use
Acronyms RAL-eve

Most Recent Events

31 Oct 2011 Planned End Date changed from 1 Mar 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
31 Oct 2011 Planned End Date changed from 1 Mar 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
07 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com